Deutsche Bank analyst Justin Bowers initiated coverage of Repligen with a Hold rating and $180 price target. The analyst launched coverage of 10 life science tools companies that have "outsized exposure" to the biopharma end market. The stocks that outperform in 2023 "will provide downside protection or are idiosyncratic," Bowers tells investors in a research note. He recommends "captains of culture" Danaher (DHR) and Thermo Fisher Scientific (TMO) for more defensive posturing. Buy-rated rated Maravai Lifesciences (MRVI), Bio-Techne (TECH) and 10X Genomics (TXG) offer novel technology and have embedded optionality, Bowers tells investors in a research note. His Hold-rated names reflect wanting better entry points andconviction in consensus estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RGEN:
- Repligen management to meet virtually with Craig-Hallum
- Repligen initiated with a Sector Perform at RBC Capital
- Repligen Corporation to Present at Upcoming Investor Conferences
- Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands
- Biotech Alert: Searches spiking for these stocks today